These 3D renderings of mouse skulls clearly show the effects of RUNX2 deficiency. Fgfr3-creER mice, which were the control group, and Fgfr3-Runx2c ...

EAU guidelines offer updated guidance on diagnosis, treatment, & follow-up of patients with metastatic & muscle-invasive ...

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.

Biomarker directed options have also emerged in advanced urothelial carcinoma. HER2 can be targeted by trastuzumab deruxtecan (requires IHC testing 2+/3+, 12% incidence in urothelial carcinoma) and ...

Importantly, based on the Thor Cohort 1 data, 4 erdafitinib is approved for FGFR3/2 alterations. With regards to ctDNA in metastatic RCC, tumor-informed panels have improved upon the low shedder ...